Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR, Urva S, Emmerson PJ, Holst JJ, D'Alessio DA, Coghlan MP, Rosenkilde MM, Campbell JE, Sloop KW. · 2020
Read Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. by Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR, Urva S, Emmerson PJ, Holst JJ, D'Alessio DA, Coghlan MP, Rosenkilde MM, Campbell JE, Sloop KW. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7526454.txt.
Description
Willard and co-authors study tirzepatide, a drug that acts on two receptors. It targets both the GIP and GLP-1 receptors. The drug was in development for type 2 diabetes and obesity.
The team measured how much the drug engages each receptor. It engaged the GIP receptor more than the GLP-1 receptor. At the GLP-1 receptor it favored cAMP signals. It drove less beta-arrestin recruitment and less receptor uptake. Tests in islet cells linked that bias to insulin release. The authors report that this mix may explain strong early trial results. Readers get a detailed drug profile at cell level.
Catalog record
| CREATOR | Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR, Urva S, Emmerson PJ, Holst JJ, D'Alessio DA, Coghlan MP, Rosenkilde MM, Campbell JE, Sloop KW. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |